Abstract
Glioblastoma (GBM) is characterized by significant sexual dimorphism, with males experiencing higher incidence and poorer outcomes. While genetic and metabolic differences have been documented, the role of the immune system in this disparity has remained largely unexplored. This study identifies that myeloid-derived suppressor cells (MDSCs), which inhibit anti-tumor immunity, drive GBM progression through sex-specific subsets. We found that monocytic MDSCs (mMDSCs) are enriched in the male tumor microenvironment, whereas granulocytic MDSCs (gMDSCs) are elevated systemically in females. These differences allow for sex-tailored therapeutic interventions: anti-proliferative agents effectively target mMDSCs in males, while IL-1β blockade inhibits gMDSC function in females. These findings suggest that immunotherapy for GBM must be stratified by sex to achieve clinical efficacy.
Introduction
Glioblastoma is the most aggressive primary brain tumor, and a notable "sex gap" persists in patient outcomes: men are 1.6 times more likely to develop the disease and generally face a worse prognosis than women. While researchers have identified some genetic and metabolic differences between male and female tumors, the host's immune system represents a critical, yet understudied, factor in this dimorphism.
Myeloid-Derived Suppressor Cells (MDSCs) are immature cells that act as "brakes" on the immune system, preventing it from mounting an effective attack against the tumor. MDSCs exist in two primary subsets: monocytic (mMDSC) and granulocytic (gMDSC). This research investigates whether these subsets contribute differently to GBM based on biological sex and whether they can be targeted individually to improve patient survival.
Methodology
The research team employed a multi-disciplinary approach combining mouse models, human patient data, and computational network medicine:
- Pre-clinical Models: Several glioma models (GL261, SB28, CT-2A) were used to observe immune cell behavior in both sexes.
- Bone Marrow Transplants: To determine if the immune system itself drives these sex differences, the researchers transplanted male bone marrow into female mice.
- Depletion and Blockade Studies: Neutralizing antibodies were used to selectively deplete specific MDSC subsets or block signaling pathways to assess survival impacts.
- Network Medicine: Using RNA-sequencing data from MDSC subsets, the team applied a network-based approach to predict which existing drugs could be repurposed to target mMDSCs versus gMDSCs.
- Human Validation: Findings were validated using 188 human GBM specimens and data from The Cancer Genome Atlas (TCGA).
Key Insights
Spatial and Functional Dimorphism
The study revealed a striking difference in where these suppressor cells congregate. mMDSCs primarily localize within the tumor microenvironment, particularly in males. In contrast, gMDSCs accumulate systemically in the blood, particularly in females.
Furthermore, the mechanisms of these cells differ by subset. mMDSCs are highly proliferative, meaning they drive suppression through rapid cell division within the tumor. gMDSCs, while less proliferative, are more active in immune-suppressive signaling, specifically through the IL-1β pathway.
The Immune System as the Driver
A pivotal bone marrow transplant experiment confirmed that the host's immune "makeup" is a primary driver of these differences. When female mice were given a male immune system, their survival outcomes shifted to resemble those of male mice, proving that the sex of the immune system, rather than just the tumor cells, dictates disease progression.
Results and Therapeutic Implications
The research demonstrated that the "one size fits all" approach to GBM treatment is suboptimal. By targeting the specific MDSC subset dominant in each sex, the researchers achieved significant survival gains:
- Male-Specific Targeting: In males, the primary immune brake is the rapidly dividing mMDSC. Treatment with Fludarabine, an anti-proliferative drug, significantly extended survival in males (30.5 days vs. 20.5 days) but had no effect on females.
- Female-Specific Targeting: In females, the primary brake is the systemic gMDSC signaling via IL-1β. Anti-IL-1β treatment significantly prolonged survival in females (with many achieving long-term survival) but provided no benefit to males.
Human Validation
Analysis of human data mirrored the mouse findings. In female patients, high expression of the gMDSC marker OLR1 and IL-1β correlated with a significantly worse prognosis. In male patients, mMDSCs were the predominant population and were confirmed to be highly proliferative (Ki-67 positive).
Conclusion
This study highlights that sexual dimorphism in MDSC prevalence, localization, and gene expression profiles offers a unique therapeutic opportunity. The findings suggest that future clinical trials for GBM must be stratified by sex. Specifically, IL-1β inhibitors (such as canakinumab) may provide substantial benefit for female patients, while specific chemotherapeutic regimens targeting cell proliferation may be more effective for males. Understanding these sex-specific immune landscapes is essential for the development of effective precision immunotherapies in glioblastoma.
Summary updated